Drug Delivery Business

  • Discovery
    • Technology
  • Research & Development
  • Preclinical Trials
  • Clinical Trials
  • Policy
  • Contract Services
  • Diagnostics

Teva aims for 25% of U.S. EpiPen market by 2020

February 19, 2019 By Sarah Faulkner Leave a Comment

Teva Pharmaceuticals - updated logo

Teva (NYSE:TEVA) expects its generic EpiPen auto-injector to claim 25% of the U.S. market by the end of this year, according to a report from Seeking Alpha. For years, Mylan‘s (NSDQ:MYL) brand-name emergency allergy device has dominated the markets. But the company faced widespread criticism in 2016 when reports revealed that Mylan hiked the price of the […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Teva Pharmaceuticals

FDA approves Teva’s digital COPD, asthma inhaler

December 26, 2018 By Sarah Faulkner 1 Comment

Teva Pharmaceuticals - updated logo

Teva (NYSE:TEVA) said this week that the FDA approved its ProAir Digihaler device – a digital inhaler that uses sensors to connect to a companion mobile app for people with asthma and chronic obstructive pulmonary disease. The company’s device features built-in sensors that can measure inspiratory flow and detect when the inhaler is used. After the […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Respiratory, Wall Street Beat Tagged With: Teva Pharmaceuticals

Teva launches generic EpiPen at the same price as existing device

November 29, 2018 By Sarah Faulkner Leave a Comment

Teva Pharmaceutical logo - updated

Teva (NYSE:TEVA) this week launched its generic version of Mylan‘s (NSDQ:MYL) EpiPen auto-injector and announced that it would sell the emergency allergy therapy for $300 – the same price as Mylan’s own generic EpiPen product. The price for Teva’s product inspired some head-scratching among patient advocates and healthcare professionals. After all, when the FDA first approved […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Technology, Wall Street Beat Tagged With: Mylan, Teva Pharmaceuticals

Teva wins FDA nod for migraine prevention drug

September 17, 2018 By Sarah Faulkner Leave a Comment

Teva Pharmaceutical's Ajovy migraine drug

Teva (NYSE:TEVA) last week won FDA approval for its humanized monoclonal antibody, Ajovy, designed to prevent migraines. The treatment, which blocks the receptor for a protein that is linked to migraine pain, is available in quarterly and monthly-injection options. Amgen‘s (NSDQ:AMGN) competitive once-monthly product won FDA approval earlier this year. Teva studied Ajovy in two Phase […]

Filed Under: Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Amgen, Teva Pharmaceuticals

Teva wins FDA nod for sublingual film to treat opioid dependence

September 10, 2018 By Sarah Faulkner Leave a Comment

Teva Pharmaceutical

The FDA last week approved Teva Pharmaceuticals (NYSE:TEVA) Cassipa sublingual film as a maintenance treatment for opioid dependence. There are a number of brand name and generic versions of buprenorphine and naloxone therapies that are delivered via a sublingual film. Teva’s product contains 16 milligrams of buprenorphine and 4 milligrams of naloxone, bringing a new dosage […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Teva Pharmaceuticals

FDA approves first generic Epipen

August 17, 2018 By Sarah Faulkner Leave a Comment

FDA

The FDA this week approved the first generic version of Mylan‘s (NSDQ:MYL) Epipen emergency allergy auto-injector. Teva Pharmaceuticals (NYSE:TEVA), which won the historic approval, plans to market the generic epinephrine auto-injector in 0.3mg and 0.15mg doses. There are other epinephrine auto-injectors on the market in the U.S., but Teva’s is the first that’s approved to directly […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Mylan, Teva Pharmaceuticals

FDA recalls heart failure, blood pressure drugs due to cancerous contaminant

July 16, 2018 By Sarah Faulkner Leave a Comment

FDA

The FDA announced last week a voluntary recall of several high blood pressure and heart failure medications containing valsartan due to a cancerous impurity. Some valsartan drugs were found to contain N-nitrosodimethylamine (NDMA), a compound that is classified as a probable human carcinogen. Not all drugs containing valsartan were recalled, the FDA noted. Teva Pharmaceuticals (NYSE:TEVA), […]

Filed Under: Cardiovascular, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Recalls, Wall Street Beat Tagged With: majorpharmaceuticals, solcohealthcare, Teva Pharmaceuticals

With groundbreaking approval, Amgen launches new class of medicine for migraine patients

May 18, 2018 By Sarah Faulkner Leave a Comment

Amgen

Amgen (NSDQ:AMGN) won FDA approval this week for its once-monthly Aimovig injection designed to prevent the onset of migraines in adults. The drug is the first of its kind – a molecule that blocks the receptor for a protein that is linked to migraine pain, the calcitronin gene-related peptide. Other major pharmaceutical companies like Eli Lilly (NYSE:LLY) […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Amgen, Eli Lilly & Co., Teva Pharmaceuticals

Tribe looks to stop patent board’s review of Restasis IP

March 20, 2018 By Sarah Faulkner Leave a Comment

gavel

Allergan (NYSE:AGN) and the St. Regis Mohawk Tribe asked the Federal Circuit last week to stop the U.S. Patent Trial and Appeal Board from reviewing the IP for Allergan’s blockbuster eye drug, Restasis. The move comes in response to the board’s February decision that sovereign immunity does not shield tribes from patent challenges. The board’s ruling […]

Filed Under: Drug-Device Combinations, Featured, Legal News, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Mylan, Teva Pharmaceuticals

Sen. McCaskill: Teva is “stonewalling” Senate investigation into opioid crisis

March 7, 2018 By Sarah Faulkner Leave a Comment

capitol hill

Sen. Claire McCaskill (D-Mo.) said that Teva Pharmaceuticals (NYSE:TEVA) is “stonewalling” a Senate probe into the the role that opioid manufacturers have in the nation’s opioid crisis. In the senator’s initial inquiries with the generic drugmaker, McCaskill requested an array of documents detailing arrangements between Teva and its customers, as well as internal reviews of pharmacies […]

Filed Under: Featured, Legal News, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Teva Pharmaceuticals

  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS